Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05916313 · ClinicalTrials.gov registry record · Phase 1
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
A Phase 1 study of Glioma, sponsored by Boehringer Ingelheim.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 12
- Study locations
NCT05916313 is a Phase 1 study of Glioma that is active but no longer recruiting, run by Boehringer Ingelheim. The registered enrollment target is 18 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (91% lower). The trial reports 12 study locations across 3 states.
The verdict
NCT05916313, a Phase 1 study of Glioma, is active but no longer recruiting, sponsored by Boehringer Ingelheim.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 12
- Study locations
Study Summary
This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful. The purpose of this study is to find out the highest dose of BI 764532 that people with a brain tumour that is positive for DLL3 can tolerate. BI 764532 is an antibody-like molecule that can attach and link together the cancer cells and T-cells of the immune system (DLL3/CD3 bispecific). This may help the immune system fight cancer. Participants get BI 764532 infusions into a vein when starting treatment. If there is benefit for the participants and if they can tolerate it, the treatment is continued. During this time, participants visit the study site at regular intervals. The total number of visits depends on how they respond to and tolerate the treatment. The first study visits include staying to monitor participants' safety. Doctors record any unwanted effects and regularly check the general health of the participants.
Conditions Studied
Interventions
- DRUG BI 764532
Study Locations (12)
Other
- Salzburg Cancer Research Institute - Salzburg
- Universitätsklinikum Frankfurt - Frankfurt
- Klinikum der Universität München AÖR - München
- Universitätsklinikum Tübingen - Tübingen
- Erasmus Medisch Centrum-ROTTERDAM-50697 - Rotterdam
- Hospital del Mar - Barcelona
- Hospital Universitario 12 de Octubre - Madrid
- Cantonal Hospital of Aarau - Aarau
- University Hospital of Lausanne - Lausanne
- University Hosp. Zurich - Zurich
California
- University of California Irvine - Orange
Tennessee
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-01-30 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05916313
The ClinicalTrials.gov registry entry for NCT05916313 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (91% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which BI 764532 is the first listed.
NCT05916313 reports 12 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05916313 about?
NCT05916313 is a clinical study titled "A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3". This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful. The purpose of this study is to find out the highest dose of BI 764532 that pe...
What is the current status of trial NCT05916313?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-01-30. Estimated completion is 2026-06-30.
What conditions does trial NCT05916313 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT05916313?
The interventions under investigation include: BI 764532 (DRUG).
Who is sponsoring clinical trial NCT05916313?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05916313 being conducted?
This trial has 12 study locations across California, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
A Study of 177Lu-PSMA-617 in People With Gliomas
RECRUITING · Phase 1
-
Hyperpolarized Imaging in Diagnosing Participants With Glioma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.